What role does Longevity DNA Test play in fertility?

A Longevity DNA Test (e.g., analyzing telomere length, FOXO3, SIRT1) is marketed to estimate biological aging. However, there is no robust evidence that such a test provides clinically meaningful information about fertility. Fertility is determined by a complex interplay of hormones, egg/sperm quality, age, lifestyle, and environmental factors—not by individual longevity-associated SNPs. While some GWAS have linked variants (e.g., in BRCA1/2 or MCM8) to age at menopause, these associations are too weak for individual prediction. Most consumer longevity tests rely on low-effect or mechanistic evidence and lack clinical validation. They may create false reassurance or unnecessary anxiety. For fertility assessment, established methods like hormone panels (AMH, FSH), ultrasound, and semen analysis are evidence-based and recommended. The role of a longevity DNA test in fertility is essentially marketing-driven, with no proven clinical utility. Evidence level: marketing.